Page 43 | Certara

Announcement

Certara Awarded European Medicines Agency Project to Assess Real-World Data Landscape for CAR-T Cell Therapies

January 22, 2025 Radnor, PA – January 22, 2025 – Certara, Inc. (Nasdaq: CERT), a…

CertaraJanuary 22, 2025

Publication

Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses

This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…

CertaraJanuary 21, 2025

Live Events

Model-Informed Drug Development: Current Landscape and Future Directions

Date: Tuesday, February 25, 2025Time: 5:30 - 8:00pmVenue: CIC Cambridge - One Broadway, Cambridge, MA…

CertaraJanuary 17, 2025

Blog

Anonymization vs. Redaction of Clinical Trial Data

January 17, 2025 The vernacular for disclosing pharmaceutical clinical trial results to the public may…

CertaraJanuary 17, 2025

Publication

Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals

Background Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of…

CertaraJanuary 16, 2025

Poster

Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model

CertaraJanuary 16, 2025

Press Release

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 15, 2025 Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted…

CertaraJanuary 15, 2025

On-Demand Webinar

Phoenix in the Future: Unveiling the Product Roadmap and the New TFL Module [APAC Webinar]

Principal Research Scientist Dr. Kristin Follman is a Principal Research Scientist at Certara, where she…

CertaraJanuary 15, 2025

Conference

EMWA Spring Conference

May 6-9, 2025 - Riga, Latvia

CertaraJanuary 15, 2025

Blog

Achieve Clinical Data Transparency with the 4 Cs of Collaboration

In this blog, we look at how you can enhance clinical data transparency and make…

CertaraJanuary 15, 2025

Certara Awarded European Medicines Agency Project to Assess Real-World Data Landscape for CAR-T Cell Therapies

Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses

Model-Informed Drug Development: Current Landscape and Future Directions

Anonymization vs. Redaction of Clinical Trial Data

Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals

Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Phoenix in the Future: Unveiling the Product Roadmap and the New TFL Module [APAC Webinar]

EMWA Spring Conference

Achieve Clinical Data Transparency with the 4 Cs of Collaboration

Newsletter sign up

Quick links

Solutions

Contact